| Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis N Bergvall, AA Petrilla, SU Karkare, R Lahoz, N Agashivala, A Pradhan, ... Journal of medical economics 17 (10), 696-707, 2014 | 111 | 2014 |
| Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study N Bergvall, C Makin, R Lahoz, N Agashivala, A Pradhan, G Capkun, ... PloS one 9 (2), e88472, 2014 | 87 | 2014 |
| “Real‐World” comparison of prasugrel with ticagrelor in patients with acute coronary syndrome treated with percutaneous coronary intervention in the United States C Larmore, MB Effron, C Molife, M DeKoven, Y Zhu, J Lu, S Karkare, ... Catheterization and Cardiovascular Interventions 88 (4), 535-544, 2016 | 83 | 2016 |
| Prevalence and predictors of antidepressant prescribing in nursing home residents in the United States SU Karkare, S Bhattacharjee, P Kamble, R Aparasu The American journal of geriatric pharmacotherapy 9 (2), 109-119, 2011 | 76 | 2011 |
| Understanding the experience of caring for children with haemophilia: cross‐sectional study of caregivers in the United States M DeKoven, S Karkare, LA Kelley, DL Cooper, H Pham, J Powers, ... Haemophilia 20 (4), 541-549, 2014 | 55 | 2014 |
| Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis N Bergvall, C Makin, R Lahoz, N Agashivala, A Pradhan, G Capkun, ... Current medical research and opinion 29 (12), 1647-1656, 2013 | 43 | 2013 |
| Impact of haemophilia with inhibitors on caregiver burden in the United States M DeKoven, S Karkare, WC Lee, LA Kelley, DL Cooper, H Pham, ... Haemophilia 20 (6), 822-830, 2014 | 36 | 2014 |
| Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus S Kabadi, J Yeaw, AK Bacani, E Tafesse, K Bos, S Karkare, M DeKoven, ... Lupus 27 (11), 1799-1809, 2018 | 28 | 2018 |
| Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States KG Saag, PE Mohr, L Esmail, AS Mudano, N Wright, T Beukelman, ... Contemporary clinical trials 33 (6), 1211-1216, 2012 | 25 | 2012 |
| Impact of a structured patient support program on adherence and persistence in basal insulin therapy for type 2 diabetes FL Zhou, J Yeaw, SU Karkare, M DeKoven, P Berhanu, T Reid BMJ Open Diabetes Research and Care 6 (1), e000593, 2018 | 16 | 2018 |
| Incorporating stakeholder perspectives in developing a translation table framework for comparative effectiveness research RE Gliklich, MB Leavy, P Velentgas, NA Dreyer, SR Tunis, P Mohr, ... Journal of Comparative Effectiveness Research 1 (3), 281-292, 2012 | 15 | 2012 |
| Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving … C Molife, F Frech-Tamas, M DeKoven, MB Effron, S Karkare, Y Zhu, ... Journal of medical economics 18 (11), 898-908, 2015 | 13 | 2015 |
| Datapoints: Psychotropic drug utilization among elderly nursing home residents in the United States S Bhattacharjee, SU Karkare, P Kamble, RR Aparasu Psychiatric Services 61 (7), 655-655, 2010 | 11 | 2010 |
| Effect of weight change on economic outcomes among persons with type 2 diabetes mellitus in the United States: beyond glycemic control S Karkare, M Fridman, T Dang-Tan, J Lu, BG Smolarz, M DeKoven, ... Journal of managed care & specialty pharmacy 25 (6), 658-668, 2019 | 10 | 2019 |
| Preoperative intravenous meloxicam for moderate-to-severe pain in the immediate post-operative period: a Phase IIIb randomized clinical trial in 55 patients undergoing primary … JD Silinsky, JE Marcet, VR Anupindi, SU Karkare, DR Shah, RJ Mack, ... Pain Management 11 (1), 9-21, 2021 | 9 | 2021 |
| Characteristics and current standard of care among veterans with major depressive disorder in the United States: a real-world data analysis X Zhao, S Karkare, AI Nash, JJ Sheehan, M Aboumrad, AM Near, ... Journal of Affective Disorders 307, 184-190, 2022 | 8 | 2022 |
| Clinical and economic outcomes of a “high-touch” clinical management program for intravenous immunoglobulin therapy J Zhu, HS Kirkham, G Ayer, CC Chen, RL Wade, SU Karkare, CH Robson, ... ClinicoEconomics and Outcomes Research, 1-12, 2017 | 7 | 2017 |
| Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial … K Joshi, D Pilon, A Shah, C Holiday, S Karkare, M Zhdanava Journal of Medical Economics 26 (1), 422-429, 2023 | 6 | 2023 |
| Characteristics of real-world commercially insured patients with treatment-resistant depression initiated on esketamine nasal spray or conventional therapies in the United States S Karkare, M Zhdanava, D Pilon, AI Nash, L Morrison, A Shah, P Lefebvre, ... Clinical Therapeutics 44 (11), 1432-1448, 2022 | 6 | 2022 |
| Relapse rates among patients with multiple sclerosis who switch from interferon therapy to fingolimod or glatiramer acetate: a retrospective US claims database analysis N Bergvall, R Lahoz, N Agashivala, A Pradhan, G Capkun-Niggli, JR Korn, ... MULTIPLE SCLEROSIS JOURNAL 19 (11), 276-276, 2013 | 4 | 2013 |
